CRESCENT BIOPHARMA, INC. financial data

Symbol
CBIO on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 702% % 54%
Debt-to-equity 19% % -90%
Return On Equity -144% % 72%
Return On Assets -114% % 24%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27,556,767 shares -57%
Common Stock, Shares, Outstanding 27,556,767 shares 2605%
Entity Public Float $177,200,000 USD 913%
Common Stock, Value, Issued $28,000 USD 2700%
Weighted Average Number of Shares Outstanding, Basic 64,522,257 shares 0.1%
Weighted Average Number of Shares Outstanding, Diluted 64,477,249 shares 1.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $138,086,000 USD 379%
General and Administrative Expense $25,390,000 USD 104%
Operating Income (Loss) $152,632,000 USD -270%
Nonoperating Income (Expense) $1,409,465 USD 131%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $17,867,000 USD
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $153,942,000 USD -272%
Earnings Per Share, Basic -0.46 USD/shares 21%
Earnings Per Share, Diluted -0.59 USD/shares -1.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $213,192,000 USD 513%
Accounts Receivable, after Allowance for Credit Loss, Current $18,000,000 USD
Other Assets, Current $5,463,000 USD 14276%
Assets, Current $236,655,000 USD 580%
Property, Plant and Equipment, Net $846,000 USD
Operating Lease, Right-of-Use Asset $1,469,000 USD
Other Assets, Noncurrent $1,216,000 USD 50%
Assets $240,293,000 USD 575%
Accounts Payable, Current $104,671 USD -86%
Employee-related Liabilities, Current $5,121,000 USD 34040%
Accrued Liabilities, Current $16,344,000 USD 635%
Contract with Customer, Liability, Current $4,156,000 USD
Liabilities, Current $36,072,000 USD 275%
Operating Lease, Liability, Noncurrent $1,209,000 USD
Liabilities $37,281,000 USD -21%
Retained Earnings (Accumulated Deficit) $171,809,000 USD -862%
Stockholders' Equity Attributable to Parent $203,012,000 USD
Liabilities and Equity $240,293,000 USD 575%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,105,992 USD 51%
Net Cash Provided by (Used in) Financing Activities $41,035,000 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 175,000,000 shares 338%
Common Stock, Shares, Issued 27,556,767 shares 2605%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,105,992 USD 51%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $213,299,000 USD 514%
Deferred Tax Assets, Valuation Allowance $47,991,000 USD 1118%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross $48,378,000 USD 1128%
Operating Lease, Liability $1,644,000 USD 2359%
Depreciation $0 USD -100%
Payments to Acquire Property, Plant, and Equipment $0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $24,607,000 USD -835%
Lessee, Operating Lease, Liability, to be Paid $1,933,000 USD 2768%
Operating Lease, Liability, Current $435,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $609,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $584,000 USD 766%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Income Tax Expense (Benefit) $0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $289,000 USD 51785%
Lessee, Operating Lease, Liability, to be Paid, Year Three $633,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $12,164,000 USD 2640%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) $0 USD
Current Income Tax Expense (Benefit) $0 USD
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $107,000 USD
Operating Lease, Payments $660,270 USD -29%
Additional Paid in Capital $370,793,000 USD 15434%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) $0 USD
Current Federal Tax Expense (Benefit) $0 USD
Deferred Tax Assets, Net of Valuation Allowance $387,000 USD
Share-based Payment Arrangement, Expense $13,300,000 USD 269%
Deferred State and Local Income Tax Expense (Benefit) $0 USD
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%